Stock 2185 SHANGHAI BIO-HEART BIOLOGICAL TECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Shanghai Bio-heart Biological Technology Co., Ltd.

Equities

2185

CNE100004JH3

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:22 2024-04-29 am EDT 		5-day change 1st Jan Change
2.15 HKD +6.44% Intraday chart for Shanghai Bio-heart Biological Technology Co., Ltd. +15.59% -37.13%
Mar. 25 Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Change of Employee Representative Supervisor CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Change of Employee Representative Supervisor
CI
Shanghai Bio-heart Biological Technology's Loss Narrows in H1
MT
Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Bioheart (02185.HK) announces clinical result for Iberis-HTN at CIT 2023
AQ
Bioheart Announces Clinical Result for Iberis-Htn At Cit 2023
CI
Shanghai Bio-heart Biological Technology Co., Ltd. Announces Management Changes
CI
Shanghai Bio-heart Injects 15 Million Yuan Into Medical Device Developer Xinzhi Medical; Shares Surge 17%
MT
Shanghai Xinzhi Medical Technology Co., Ltd. announced that it expects to receive CNY 15 million in funding from Shanghai Bio-heart Biological Technology Co., Ltd.
CI
Shanghai Bio-heart Biological Technology Achieves Primary Clinical Endpoint for Catheter System; Shares Climb 44%
MT
Shanghai Bio-heart Biological Technology Co., Ltd. Announces Achievement of Primary Clinical Endpoint in the Iberis-HTN
CI
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Ji Chen Would Not Offer Himself for Re-Election as A Non-Executive Director
CI
Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Shanghai Bio-heart Biological Technology Co., Ltd. Announces First Patient Enrollment in the RADIUS-HTN Trial
CI
Shanghai Bio-heart Biological Technology Co., Ltd.(SEHK:2185) dropped from S&P Global BMI Index
CI
Certain H Shares of Shanghai Bio-heart Biological Technology Co., Ltd. are subject to a Lock-Up Agreement Ending on 23-DEC-2022.
CI
Shanghai Bio-heart to Conduct Clinical Trials in Japan for Restenosis Treatment
MT
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Clinical Trial of Sirolimus Drug-Eluting Balloon for the Treatment of In-Stent Restenosis
CI
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Its Iberis® multi-electrode RDN system product Approve by the Ethics Committee of Ruijin Hainan Hospital
CI
Shanghai Bio-heart Biological Technology Gets Chinese Regulator’s Thumbs Up for H Shares
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2185 Stock
  4. News Shanghai Bio-heart Biological Technology Co., Ltd.